




TERTHERA

TERBIUM THERANOSTICS

TERBIUM-161 NCA Carrier free lanthanide Terbium-161, produced by neutron activation of Gadolinium-160, is a promising radionuclide for RLT exhibiting comparable chemical characteristics to known radiolanthanides. Early research suggests that as much as 16-fold increase in Auger and conversion electrons is emitted by Terbium-161 resulting in potential 3-fold higher cellular absorbed dose improving anti-tumor capabilities for primary and (micro)metastasized cancers.



Terbium-161 NCA in aqueous 0.05M HCl
Half-life 6.9 days; Decays to stable Dy-161



E β 154KeV (average)
E γ 49keV (17%) 75keV (10%)



Factor >3 higher absorbed dose (average)
High LET Conversion & Auger electrons



Chemical purity >99% (ICP-MS)
Radiochemical purity >99% (TLC)



Potential indications prostate, breast,
neuroendocrine and solid cancers



GMP Grade product launched in 2025
Global availability Tb-161N CA since 2022

OUR MISSION At TerThera we aim to meet the growing demand in cancer healthcare by introducing Terbium-161 (NCA) as a new treatment option and as an emerging alternative to enhance Radioligand Therapy (RLT).

**VISIT US AT THE
EANM 2026**

Minervum 7070
4817 ZK Breda
The Netherlands



+31(0)76 - 8200970



sales@terthera.com



www.terthera.com